Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)

NCT00506948 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

13

Enrollment

OTHER

Sponsor class

Stopped Halted due to high incidence of veno-oclusive disease of the liver.

Conditions

Hematological Malignancies
Myelodysplastic Syndrome
Leukemia
Lymphoma

Interventions

DRUG: Mycophenolate Mofetil (MMF)
DRUG: Thymoglobulin
DRUG: Sirolimus
PROCEDURE: Stem Cell Transplant

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]